JP2009513647A - 分岐鎖アミノ酸の使用方法 - Google Patents
分岐鎖アミノ酸の使用方法 Download PDFInfo
- Publication number
- JP2009513647A JP2009513647A JP2008537904A JP2008537904A JP2009513647A JP 2009513647 A JP2009513647 A JP 2009513647A JP 2008537904 A JP2008537904 A JP 2008537904A JP 2008537904 A JP2008537904 A JP 2008537904A JP 2009513647 A JP2009513647 A JP 2009513647A
- Authority
- JP
- Japan
- Prior art keywords
- nutritional product
- orally administrable
- dipeptide
- administrable nutritional
- alanyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000005693 branched-chain amino acids Chemical class 0.000 title claims abstract description 32
- 108010016626 Dipeptides Proteins 0.000 claims abstract description 34
- 235000016709 nutrition Nutrition 0.000 claims abstract description 32
- RDIKFPRVLJLMER-BQBZGAKWSA-N Ala-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](C)N RDIKFPRVLJLMER-BQBZGAKWSA-N 0.000 claims abstract description 10
- ZSOICJZJSRWNHX-ACZMJKKPSA-N Ala-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)[C@H](C)[NH3+] ZSOICJZJSRWNHX-ACZMJKKPSA-N 0.000 claims abstract description 7
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 claims abstract description 7
- DKEXFJVMVGETOO-LURJTMIESA-N Gly-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)CN DKEXFJVMVGETOO-LURJTMIESA-N 0.000 claims abstract description 6
- KGVHCTWYMPWEGN-UHFFFAOYSA-N glycyl-isoleucine Chemical compound CCC(C)C(C(O)=O)NC(=O)CN KGVHCTWYMPWEGN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 108010050848 glycylleucine Proteins 0.000 claims abstract description 6
- 108010037850 glycylvaline Proteins 0.000 claims abstract description 6
- STKYPAFSDFAEPH-LURJTMIESA-N glycylvaline Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)CN STKYPAFSDFAEPH-LURJTMIESA-N 0.000 claims abstract description 5
- 238000000034 method Methods 0.000 claims description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 15
- 235000019658 bitter taste Nutrition 0.000 claims description 14
- 235000018102 proteins Nutrition 0.000 claims description 13
- 108090000623 proteins and genes Proteins 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 12
- 201000010099 disease Diseases 0.000 claims description 11
- 208000030507 AIDS Diseases 0.000 claims description 8
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 8
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 206010006895 Cachexia Diseases 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 239000000796 flavoring agent Substances 0.000 claims description 7
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims description 6
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims description 6
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 6
- 235000014633 carbohydrates Nutrition 0.000 claims description 6
- 150000001720 carbohydrates Chemical class 0.000 claims description 6
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 6
- 229930195729 fatty acid Natural products 0.000 claims description 6
- 239000000194 fatty acid Substances 0.000 claims description 6
- 150000004665 fatty acids Chemical class 0.000 claims description 6
- 206010022437 insomnia Diseases 0.000 claims description 6
- 239000000835 fiber Substances 0.000 claims description 5
- 235000013355 food flavoring agent Nutrition 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 208000019423 liver disease Diseases 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 208000001076 sarcopenia Diseases 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- 239000011782 vitamin Substances 0.000 claims description 5
- 235000013343 vitamin Nutrition 0.000 claims description 5
- 229940088594 vitamin Drugs 0.000 claims description 5
- 229930003231 vitamin Natural products 0.000 claims description 5
- 208000037157 Azotemia Diseases 0.000 claims description 4
- 206010007558 Cardiac failure chronic Diseases 0.000 claims description 4
- 206010016654 Fibrosis Diseases 0.000 claims description 4
- 239000004471 Glycine Substances 0.000 claims description 4
- 206010020772 Hypertension Diseases 0.000 claims description 4
- 208000013016 Hypoglycemia Diseases 0.000 claims description 4
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims description 4
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 claims description 4
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 claims description 4
- 235000004279 alanine Nutrition 0.000 claims description 4
- 201000011510 cancer Diseases 0.000 claims description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 4
- 230000007882 cirrhosis Effects 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 208000035475 disorder Diseases 0.000 claims description 4
- 208000020694 gallbladder disease Diseases 0.000 claims description 4
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 4
- 229960000310 isoleucine Drugs 0.000 claims description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 claims description 4
- 208000017169 kidney disease Diseases 0.000 claims description 4
- 230000005976 liver dysfunction Effects 0.000 claims description 4
- 235000010755 mineral Nutrition 0.000 claims description 4
- 208000009852 uremia Diseases 0.000 claims description 4
- 239000004474 valine Substances 0.000 claims description 4
- 208000016261 weight loss Diseases 0.000 claims description 4
- 230000004580 weight loss Effects 0.000 claims description 4
- 208000007848 Alcoholism Diseases 0.000 claims description 3
- 206010008748 Chorea Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 208000018737 Parkinson disease Diseases 0.000 claims description 3
- 206010040047 Sepsis Diseases 0.000 claims description 3
- 208000012601 choreatic disease Diseases 0.000 claims description 3
- 206010012601 diabetes mellitus Diseases 0.000 claims description 3
- 238000001631 haemodialysis Methods 0.000 claims description 3
- 230000000322 hemodialysis Effects 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 208000011580 syndromic disease Diseases 0.000 claims description 3
- 230000009967 tasteless effect Effects 0.000 claims description 3
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 208000011117 substance-related disease Diseases 0.000 claims description 2
- 235000000346 sugar Nutrition 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims 4
- 208000003770 biliary dyskinesia Diseases 0.000 claims 1
- 230000000142 dyskinetic effect Effects 0.000 claims 1
- 229940024606 amino acid Drugs 0.000 description 19
- 235000001014 amino acid Nutrition 0.000 description 19
- 150000001413 amino acids Chemical class 0.000 description 19
- 239000000047 product Substances 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- 230000009469 supplementation Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 230000014616 translation Effects 0.000 description 5
- 238000001243 protein synthesis Methods 0.000 description 4
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- 201000000585 muscular atrophy Diseases 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 239000000411 inducer Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 201000006370 kidney failure Diseases 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000000873 masking effect Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 102100030840 AT-rich interactive domain-containing protein 4B Human genes 0.000 description 1
- 102000005862 Angiotensin II Human genes 0.000 description 1
- 101800000733 Angiotensin-2 Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000012661 Dyskinesia Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101000792935 Homo sapiens AT-rich interactive domain-containing protein 4B Proteins 0.000 description 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 description 1
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 description 1
- 235000009499 Vanilla fragrans Nutrition 0.000 description 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 description 1
- 244000263375 Vanilla tahitensis Species 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 235000005550 amino acid supplement Nutrition 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 229950006323 angiotensin ii Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 230000037147 athletic performance Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- -1 enzymes Chemical class 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 235000019615 sensations Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 230000014621 translational initiation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
【選択図】なし
Description
1 技術分野
本発明は全般的に、分岐鎖アミノ酸の使用、より詳細には、経口投与可能な栄養製品の苦味を減少させるための分岐鎖アミノ酸を含むジペプチドの使用に関する。
アミノ酸は、タンパク質の単量体構成単位であり、タンパク質はさらには、酵素、抗体、ホルモン、イオン・小分子用の輸送分子、コラーゲン、及び筋組織を含めた広範囲な生体化合物を構成する。アミノ酸は、水中での溶解度に基づいて、より詳細には、側鎖の極性に基づいて、疎水性又は親水性と見なされる。極性側鎖を有するアミノ酸は親水性であり、一方非極性側鎖を有するアミノ酸は疎水性である。アミノ酸の溶解度は、タンパク質の構造を部分的に決定する。親水性アミノ酸は、タンパク質の表面を構成する傾向があり、一方疎水性アミノ酸は、タンパク質の水不溶性の内側部分を構成する傾向がある。
本発明は、分岐鎖アミノ酸(BCAA)を含んだジペプチドを含む経口投与可能な栄養製品を提供する。本発明の栄養製品は、疾患、障害、ストレス、又は加齢の影響を患っている個人における、窒素バランスの維持又は促進に使用できる。本発明の製品は、運動競技の実演又は他の身体的に激しい活動に従事している個人などの、窒素不均衡を起こす危険性の恐れはあるが、それ以外は健康な個人において、窒素バランスの維持又は促進に同様に使用し得る。一実施形態では、この栄養製品は、下記の少なくとも1つから選択されるジペプチドを含む。アラニル−ロイシン、アラニル−イソロイシン、アラニル−バリン、グリシル−ロイシン、グリシル−イソロイシン、及びグリシル−バリン。
上記で示したように、本発明は、経口投与可能な栄養製品の苦味を減少させるため、分岐鎖アミノ酸(BCAA)を含むジペプチドの使用に関する。
Claims (19)
- 少なくとも1種の分岐鎖アミノ酸を含んだ少なくとも1種のジペプチドを含み、
前記少なくとも1種のジペプチドが、遊離の分岐鎖アミノ酸の苦味よりも少ない苦味を示す、
経口投与可能な栄養製品。 - 前記分岐鎖アミノ酸が、ロイシン、イソロイシン、及びバリンからなる群から選択される、請求項1に記載の経口投与可能な栄養製品。
- 前記少なくとも1種のジペプチドが、アラニン及びグリシンの一方をさらに含む、請求項1に記載の経口投与可能な栄養製品。
- 前記ジペプチドが、アラニル−ロイシン、アラニル−イソロイシン、アラニル−バリン、グリシル−ロイシン、グリシル−イソロイシン、及びグリシル−バリンからなる群から選択される、請求項3に記載の経口投与可能な栄養製品。
- 下記の少なくとも1種:タンパク質、繊維、脂肪酸、ビタミン、ミネラル、炭水化物、香味剤、薬剤、及び治療剤をさらに含む、請求項1に記載の経口投与可能な栄養製品。
- 少なくとも1種の分岐鎖アミノ酸を含んだ少なくとも1種のジペプチドの有効量を含み、前記ジペプチドが遊離分岐鎖アミノ酸の苦味よりも少ない苦味を示す経口投与可能な栄養製品を個人に投与するステップ
を含む、
疾患及び障害の少なくとも1つを患っている個人を、経口投与可能な栄養製品で治療する方法。 - 前記分岐鎖アミノ酸が、ロイシン、イソロイシン、及びバリンからなる群から選択される、請求項6に記載の方法。
- 前記ジペプチドが、アラニン及びグリシンの1つをさらに含む、請求項6に記載の方法。
- 前記ジペプチドが、アラニル−ロイシン、アラニル−イソロイシン、アラニル−バリン、グリシル−ロイシン、グリシル−イソロイシン、及びグリシル−バリンからなる群から選択される、請求項8に記載の方法。
- 前記経口投与可能な栄養製品が、下記の少なくとも1種:タンパク質、繊維、脂肪酸、ビタミン、ミネラル、糖、炭水化物、香味剤、薬剤、及び治療剤をさらに含む、請求項6に記載の方法。
- 前記経口投与可能な栄養製品が、下記の各々の少なくとも1種:タンパク質、脂肪酸、炭水化物をさらに含む、請求項6に記載の方法。
- 前記経口投与可能な栄養製品が、少なくとも1種の繊維をさらに含む、請求項11に記載の方法。
- 前記経口投与可能な栄養製品が、少なくとも1種のビタミン、及び少なくとも1種のミネラルをさらに含む、請求項12に記載の方法。
- 前記経口投与可能な栄養製品が、少なくとも1種の香味剤をさらに含む、請求項12に記載の方法。
- 前記経口投与可能な栄養製品が、薬剤又は治療剤、並びに下記の各々の少なくとも1種:タンパク質、脂肪酸、及び炭水化物をさらに含む、請求項6に記載の方法。
- 前記経口投与可能な栄養製品が、下記の各々の少なくとも1種:タンパク質、繊維、脂肪酸、ビタミン、ミネラル、炭水化物、香味剤、薬剤、及び治療剤をさらに含む、請求項6に記載の方法。
- 前記個人が、下記の少なくとも1種:カヘキシー、癌、腫瘍による体重減少、敗血症、慢性心不全、関節リウマチ、後天性免疫不全症候群(AIDS)、筋肉減少症、糖尿病、高血圧症、高濃度血清コレステロール、高濃度トリグリセリド、パーキンソン病、不眠、薬物嗜癖、アルコール嗜癖、疼痛、不眠、低血糖、肝硬変を含めた肝機能障害、胆嚢障害、舞踏病、運動異常症、及び尿毒症を含めた腎障害を患っている、請求項6に記載の方法。
- 前記個人が、下記の少なくとも1種:カヘキシー、癌、腫瘍による体重減少、慢性心不全、後天性免疫不全症候群(AIDS)、筋肉減少症、高血圧症、高濃度血清コレステロール、高濃度トリグリセリド、低血糖、肝硬変を含めた肝機能障害、胆嚢障害、運動異常症、及び尿毒症を含めた腎障害を患っている、請求項6に記載の方法。
- 前記個人が血液透析を受けている、請求項6に記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US73145005P | 2005-10-28 | 2005-10-28 | |
PCT/US2006/041615 WO2007053390A2 (en) | 2005-10-28 | 2006-10-26 | Methods for the use of branched chain amino acids |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2009513647A true JP2009513647A (ja) | 2009-04-02 |
Family
ID=38006384
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2008537904A Pending JP2009513647A (ja) | 2005-10-28 | 2006-10-26 | 分岐鎖アミノ酸の使用方法 |
Country Status (11)
Country | Link |
---|---|
US (3) | US7989418B2 (ja) |
EP (3) | EP2340725A1 (ja) |
JP (1) | JP2009513647A (ja) |
CN (1) | CN101282657A (ja) |
AU (1) | AU2006309040B2 (ja) |
BR (1) | BRPI0617824A2 (ja) |
CA (1) | CA2627566A1 (ja) |
IL (1) | IL190483A0 (ja) |
RU (1) | RU2008121259A (ja) |
WO (1) | WO2007053390A2 (ja) |
ZA (1) | ZA200804611B (ja) |
Families Citing this family (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0617824A2 (pt) * | 2005-10-28 | 2011-08-09 | Nestec Sa | métodos para o uso de aminoácidos de cadeia ramificada |
CA2631647A1 (en) * | 2005-11-30 | 2007-06-07 | Nestec S.A. | Use of branched-chain amino acids for the treatment of muscle loss |
EP2039366A4 (en) * | 2006-04-21 | 2010-01-06 | Meiji Seika Kaisha | COMPOSITION CONTAINING PEPTIDE AS ACTIVE INGREDIENT |
US10343582B2 (en) | 2010-02-06 | 2019-07-09 | Ronald R. Nespor | Flatbed tow truck assembly and method of use |
SI2603232T1 (sl) | 2010-08-11 | 2020-03-31 | Ironwood Pharmaceuticals, Inc. | Stabilne formulacije linaklotida |
JP2015518470A (ja) | 2012-03-26 | 2015-07-02 | プロニュートリア・インコーポレイテッドPronutria, Inc. | 栄養タンパク質および方法 |
US9598474B2 (en) | 2012-03-26 | 2017-03-21 | Axcella Health, Inc. | Nutritive fragments, proteins and methods |
WO2013148329A1 (en) | 2012-03-26 | 2013-10-03 | Pronutria, Inc. | Charged nutritive proteins and methods |
AU2013240271A1 (en) | 2012-03-26 | 2014-10-02 | Axcella Health Inc. | Nutritive fragments, proteins and methods |
WO2014134225A2 (en) * | 2013-02-26 | 2014-09-04 | Pronutria, Inc. | Nutritive polypeptides, formulations and methods for treating disease and improving muscle health and maintenance |
EP2986113B1 (en) * | 2013-04-16 | 2020-08-26 | The Children's Hospital of Philadelphia | Compositions and methods for the treatment of brain injury |
KR20160056941A (ko) | 2013-09-25 | 2016-05-20 | 프로뉴트리아 바이오사이언시스, 인코퍼레이티드 | 당뇨병 및 비만의 예방 및 치료를 위한 조성물 및 제형, 그리고 글루코스 및 열량 제어에서 이들의 생성방법 및 용도 |
JP5828990B2 (ja) * | 2013-09-30 | 2015-12-09 | リンテック株式会社 | 樹脂膜形成用複合シート |
JOP20190146A1 (ar) | 2016-12-19 | 2019-06-18 | Axcella Health Inc | تركيبات حمض أميني وطرق لمعالجة أمراض الكبد |
CU20200012A7 (es) | 2017-08-14 | 2021-02-04 | Axcella Health Inc | Composiciones de aminoácidos para el tratamiento de enfermedad hepática |
JP2021527670A (ja) | 2018-06-20 | 2021-10-14 | アクセラ・ヘルス・インコーポレイテッドAxcella Health Inc. | 筋肉中の脂肪浸潤の治療のための組成物及び方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61247354A (ja) * | 1984-11-19 | 1986-11-04 | ザ モンテフイオル ホスピタル アソシエ−シヨン オブ ウエスタ−ン ペンシルバニア | 栄養素組成物 |
JPH0222232A (ja) * | 1988-05-11 | 1990-01-25 | Morishita Pharmaceut Co Ltd | 栄養輸液組成物 |
JPH03127737A (ja) * | 1989-10-13 | 1991-05-30 | Otsuka Pharmaceut Factory Inc | 分岐鎖アミノ酸製剤 |
JPH11508282A (ja) * | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | 悪液質および食欲不振の予防および治療方法 |
JP2003024012A (ja) * | 2001-07-18 | 2003-01-28 | National Institute Of Advanced Industrial & Technology | アンジオテンシンi変換酵素阻害剤及び血圧降下性機能食品 |
JP2005336078A (ja) * | 2004-05-25 | 2005-12-08 | Nippon Paper Chemicals Co Ltd | マスキング剤 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4244816A (en) * | 1979-01-22 | 1981-01-13 | Exxon Research & Engineering Co. | Liquid membrane capsule systems resistant to coalescence by means of an irreversible coating |
US5034377A (en) | 1984-11-19 | 1991-07-23 | Montefiore Hospital Association Of Western Pennsylvania | Aqueous nutrient compositions comprising oligopeptides |
US20020102674A1 (en) * | 1987-05-20 | 2002-08-01 | David M Anderson | Stabilized microporous materials |
JPH0421635A (ja) * | 1990-05-16 | 1992-01-24 | Suntory Ltd | アセトアルデヒドの毒性抑制剤およびアセトアルデヒドの毒性抑制に有効な飲食物 |
US20030198617A1 (en) * | 1993-03-04 | 2003-10-23 | Lawrence Green | Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof |
US5374428A (en) * | 1993-03-23 | 1994-12-20 | Kansas State University Research Foundation | Supplementation of protein diets with di- and tripeptides |
US20020044988A1 (en) * | 2000-08-22 | 2002-04-18 | Fuchs Eileen C. | Nutritional composition and method for improving protein deposition |
US20030099689A1 (en) * | 2001-08-31 | 2003-05-29 | Ohio State Research Foundation | Dietary formulations including peptides |
US20040087490A1 (en) * | 2002-09-20 | 2004-05-06 | Troup John P. | Nutritional compositions |
KR20050102637A (ko) * | 2003-02-06 | 2005-10-26 | 가부시키가이샤 오츠까 세이야꾸 고죠 | 주술기 혈당치 상승 억제제 |
WO2004078780A1 (en) * | 2003-03-04 | 2004-09-16 | Pepharm R&D Limited | Pharmaceutical composition containing l-seryl-l-leucine |
CN1780846A (zh) | 2003-03-05 | 2006-05-31 | Rib-X医药品有限公司 | 双官能杂环化合物及其制备和使用方法 |
US20040224037A1 (en) * | 2003-04-28 | 2004-11-11 | Gonzalo Romero-Matos | Devastating treatment against hiv/aids with capsaicin |
PL1669463T3 (pl) * | 2003-08-01 | 2009-02-27 | Calpis Co Ltd | Hydrolizat kazeiny, sposób jego wytwarzania i zastosowanie |
US7846902B2 (en) * | 2005-09-20 | 2010-12-07 | Kyowa Hakko Bio Co., Ltd. | Dipeptide-comprising composition for oral administration |
BRPI0617824A2 (pt) * | 2005-10-28 | 2011-08-09 | Nestec Sa | métodos para o uso de aminoácidos de cadeia ramificada |
CA2631647A1 (en) * | 2005-11-30 | 2007-06-07 | Nestec S.A. | Use of branched-chain amino acids for the treatment of muscle loss |
BRPI0621481A2 (pt) * | 2006-03-23 | 2011-12-13 | Nestec Sa | suplemento nutricional de alta caloria |
-
2006
- 2006-10-26 BR BRPI0617824-3A patent/BRPI0617824A2/pt not_active IP Right Cessation
- 2006-10-26 JP JP2008537904A patent/JP2009513647A/ja active Pending
- 2006-10-26 EP EP11002605A patent/EP2340725A1/en not_active Withdrawn
- 2006-10-26 AU AU2006309040A patent/AU2006309040B2/en not_active Ceased
- 2006-10-26 CA CA002627566A patent/CA2627566A1/en not_active Abandoned
- 2006-10-26 CN CNA2006800371880A patent/CN101282657A/zh active Pending
- 2006-10-26 US US12/089,970 patent/US7989418B2/en not_active Expired - Fee Related
- 2006-10-26 EP EP06836521A patent/EP1940252A2/en not_active Withdrawn
- 2006-10-26 RU RU2008121259/13A patent/RU2008121259A/ru unknown
- 2006-10-26 EP EP13168929.1A patent/EP2630874A1/en not_active Withdrawn
- 2006-10-26 WO PCT/US2006/041615 patent/WO2007053390A2/en active Application Filing
-
2008
- 2008-03-27 IL IL190483A patent/IL190483A0/en unknown
- 2008-05-27 ZA ZA200804611A patent/ZA200804611B/xx unknown
-
2010
- 2010-10-08 US US12/901,178 patent/US8486888B2/en not_active Expired - Fee Related
-
2013
- 2013-04-11 US US13/861,030 patent/US20130225510A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS61247354A (ja) * | 1984-11-19 | 1986-11-04 | ザ モンテフイオル ホスピタル アソシエ−シヨン オブ ウエスタ−ン ペンシルバニア | 栄養素組成物 |
JPH0222232A (ja) * | 1988-05-11 | 1990-01-25 | Morishita Pharmaceut Co Ltd | 栄養輸液組成物 |
JPH03127737A (ja) * | 1989-10-13 | 1991-05-30 | Otsuka Pharmaceut Factory Inc | 分岐鎖アミノ酸製剤 |
JPH11508282A (ja) * | 1996-04-25 | 1999-07-21 | アボツト・ラボラトリーズ | 悪液質および食欲不振の予防および治療方法 |
JP2003024012A (ja) * | 2001-07-18 | 2003-01-28 | National Institute Of Advanced Industrial & Technology | アンジオテンシンi変換酵素阻害剤及び血圧降下性機能食品 |
JP2005336078A (ja) * | 2004-05-25 | 2005-12-08 | Nippon Paper Chemicals Co Ltd | マスキング剤 |
Non-Patent Citations (1)
Title |
---|
日本消化器病学会雑誌, vol. 88, no. 12, JPN6011015620, 1991, pages 2837 - 2846, ISSN: 0002030257 * |
Also Published As
Publication number | Publication date |
---|---|
CA2627566A1 (en) | 2007-05-10 |
BRPI0617824A2 (pt) | 2011-08-09 |
US8486888B2 (en) | 2013-07-16 |
US7989418B2 (en) | 2011-08-02 |
WO2007053390A2 (en) | 2007-05-10 |
US20090170786A1 (en) | 2009-07-02 |
WO2007053390A3 (en) | 2007-08-09 |
AU2006309040B2 (en) | 2011-10-06 |
US20110028392A1 (en) | 2011-02-03 |
IL190483A0 (en) | 2008-11-03 |
RU2008121259A (ru) | 2009-12-10 |
EP2630874A1 (en) | 2013-08-28 |
US20130225510A1 (en) | 2013-08-29 |
EP1940252A2 (en) | 2008-07-09 |
AU2006309040A1 (en) | 2007-05-10 |
CN101282657A (zh) | 2008-10-08 |
ZA200804611B (en) | 2009-12-30 |
EP2340725A1 (en) | 2011-07-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2006309040B2 (en) | Methods for the use of branched chain amino acids | |
USRE39705E1 (en) | Method of treating glutathione deficient mammals | |
RU2444355C2 (ru) | Способы лечения с применением цитруллина | |
ES2363442T3 (es) | Combinación que comprende al menos una aminoácido y un inhibidor de pkr para utilizar en el tratamiento de la pérdida de masa muscular. | |
DK2440232T3 (en) | Medicinal foods containing glycomacropeptide for the nutritional treatment of phenylketonuria and other metabolic disorders | |
TWI280136B (en) | Composition containing dipeptide of histidine and alanine for reducing uric acid | |
US20080275120A1 (en) | Leucine rich composition | |
JP5775668B2 (ja) | アミノ酸組成物を含有する疲労防止剤 | |
JP2014506254A (ja) | β−ヒドロキシ−β−メチルブチレートを用いる廃用期間後の筋肉回復を促進させるための方法 | |
JPS6339821A (ja) | 関節の治療薬 | |
US9961932B2 (en) | Muscle preservation in overweight or obese adult during weight loss program | |
JP5501395B2 (ja) | N−メチル−d−アスパレート受容体のnr2−bサブユニットが関与している症候群または病態と闘うための治療薬 | |
KR20220002151A (ko) | 티로신을 유효성분으로 함유하는 단백질 내 티로신의 니트로화에 의한 질환의 예방, 개선 또는 치료용 조성물 | |
JP2011504464A (ja) | 新規血圧降下組成物 | |
JPH04506597A (ja) | 大型中性アミノ酸の食後血漿濃度の低下 | |
Davidova et al. | Pharmacological activity of amino acids and prospects for the creation of drugs based on them | |
US20120122984A1 (en) | Methods of Treating Lipomas and Liposarcomas | |
JP2001026753A (ja) | 高血圧症予防又は治療用組成物 | |
JP5317456B2 (ja) | 内因性オピオイドペプチドの血中分泌促進用組成物 | |
CN114025780A (zh) | 含有支链氨基酸的新组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110329 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110627 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20111004 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120206 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20120409 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20120525 |